If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> RHEUMATOLOGY<br /> ISSN 2056-6395 Vol 3.1 • July 2016 • emjreviews.com<br /> INSIDE<br /> Review of<br /> EULAR 2016<br /> London, UK<br /> CONTENTS<br /> EDITORIAL BOARD......................................................................................................................................... 5<br /> CONGRESS REVIEW........................................................................................................................................ 10<br /> • Review of the 17th European League Against Rheumatology (EULAR) Annual<br /> Congress of Rheumatology, held in London, UK, 8th–11th June 2016<br /> SYMPOSIUM REVIEWS<br /> • INTRODUCING NEW BIOSIMILARS INTO CURRENT TREATMENT ALGORITHMS..................... 28<br /> • OPTIMISING PATIENT OUTCOMES THROUGHOUT THE RHEUMATOID ARTHRITIS PATIENT<br /> JOURNEY: THE EXCEPTION, THE STANDARD, AND THE RULE.<a title="EMJ Rheumatology 3.1 2016 page 1" href="http://viewer.zmags.com/publication/054e0926?page=1"> RHEUMATOLOGY ISSN 2056-6395 </a> <a title="EMJ Rheumatology 3.1 2016 page 2" href="http://viewer.zmags.com/publication/054e0926?page=2"> CONTENTS EDITORIAL BOARD.......................</a> <a title="EMJ Rheumatology 3.1 2016 page 3" href="http://viewer.zmags.com/publication/054e0926?page=3"> RHEUMATOLOGY • THE RELEVANCE OF HYPERURICAEMI</a> <a title="EMJ Rheumatology 3.1 2016 page 4" href="http://viewer.zmags.com/publication/054e0926?page=4"> gehealthcare.com Solutions to h</a> <a title="EMJ Rheumatology 3.1 2016 page 5" href="http://viewer.zmags.com/publication/054e0926?page=5"> Editorial Board Editor-in-Chief: Dr Ian Chik</a> <a title="EMJ Rheumatology 3.1 2016 page 6" href="http://viewer.zmags.com/publication/054e0926?page=6"> SUBSCRIBE TOTHEEMJ NEWSLETTER NwEwwW.newSs.eLmjEr</a> <a title="EMJ Rheumatology 3.1 2016 page 7" href="http://viewer.zmags.com/publication/054e0926?page=7"> Welcome Welcome to EMJ Rheumatology. Here you </a> <a title="EMJ Rheumatology 3.1 2016 page 8" href="http://viewer.zmags.com/publication/054e0926?page=8"> HYPERURICEMIA WITH DEPOSITION: A SYSTEMIC DISEASE</a> <a title="EMJ Rheumatology 3.1 2016 page 9" href="http://viewer.zmags.com/publication/054e0926?page=9"> Foreword </a> <a title="EMJ Rheumatology 3.1 2016 page 10" href="http://viewer.zmags.com/publication/054e0926?page=10"> 10 RHEUMATOLOGY • July 2016 </a> <a title="EMJ Rheumatology 3.1 2016 page 11" href="http://viewer.zmags.com/publication/054e0926?page=11"> RHEUMATOLOGY • July 2016 </a> <a title="EMJ Rheumatology 3.1 2016 page 12" href="http://viewer.zmags.com/publication/054e0926?page=12"> 12 RHEUMATOLOGY • July 2016 </a> <a title="EMJ Rheumatology 3.1 2016 page 13" href="http://viewer.zmags.com/publication/054e0926?page=13"> Congress Highlights Discovery of a G</a> <a title="EMJ Rheumatology 3.1 2016 page 14" href="http://viewer.zmags.com/publication/054e0926?page=14"> the management of SLE, and ultimately t</a> <a title="EMJ Rheumatology 3.1 2016 page 15" href="http://viewer.zmags.com/publication/054e0926?page=15"> Genetic profiling is an approach which could provi</a> <a title="EMJ Rheumatology 3.1 2016 page 16" href="http://viewer.zmags.com/publication/054e0926?page=16"> There is therefore a need to develop a new tool t</a> <a title="EMJ Rheumatology 3.1 2016 page 17" href="http://viewer.zmags.com/publication/054e0926?page=17"> These findings are exciting as anti-CCP antibodies</a> <a title="EMJ Rheumatology 3.1 2016 page 18" href="http://viewer.zmags.com/publication/054e0926?page=18"> and restricted movement of joints, pain</a> <a title="EMJ Rheumatology 3.1 2016 page 19" href="http://viewer.zmags.com/publication/054e0926?page=19"> can have a seriously detrimental impact on a coup</a> <a title="EMJ Rheumatology 3.1 2016 page 20" href="http://viewer.zmags.com/publication/054e0926?page=20"> controls, with a between-group difference of 2.20</a> <a title="EMJ Rheumatology 3.1 2016 page 21" href="http://viewer.zmags.com/publication/054e0926?page=21"> Dr Arumugam Moorthy, Department of Rheuma</a> <a title="EMJ Rheumatology 3.1 2016 page 22" href="http://viewer.zmags.com/publication/054e0926?page=22"> Association Between Juvenile Inflammatory Arthriti</a> <a title="EMJ Rheumatology 3.1 2016 page 23" href="http://viewer.zmags.com/publication/054e0926?page=23"> the drug from the body, potentially leading to a </a> <a title="EMJ Rheumatology 3.1 2016 page 24" href="http://viewer.zmags.com/publication/054e0926?page=24"> Other research presented at EULAR 2016 demon</a> <a title="EMJ Rheumatology 3.1 2016 page 25" href="http://viewer.zmags.com/publication/054e0926?page=25"> Dr Yasser El Miedany, Department o</a> <a title="EMJ Rheumatology 3.1 2016 page 26" href="http://viewer.zmags.com/publication/054e0926?page=26"> Methotrexate is often the first step of drug treat</a> <a title="EMJ Rheumatology 3.1 2016 page 27" href="http://viewer.zmags.com/publication/054e0926?page=27"> physician evaluation of the disease was</a> <a title="EMJ Rheumatology 3.1 2016 page 28" href="http://viewer.zmags.com/publication/054e0926?page=28"> INTRODUCING NEW BIOSIMILARS INTO CURRENT TREATM</a> <a title="EMJ Rheumatology 3.1 2016 page 29" href="http://viewer.zmags.com/publication/054e0926?page=29"> moderate-to-severe rheumatoid arthritis despite t</a> <a title="EMJ Rheumatology 3.1 2016 page 30" href="http://viewer.zmags.com/publication/054e0926?page=30"> antibodies, published in 2012,6 and the guideline</a> <a title="EMJ Rheumatology 3.1 2016 page 31" href="http://viewer.zmags.com/publication/054e0926?page=31"> Residual uncertainty (potential for clinical diff</a> <a title="EMJ Rheumatology 3.1 2016 page 32" href="http://viewer.zmags.com/publication/054e0926?page=32"> To show pharmacokinetic equivalence, </a> <a title="EMJ Rheumatology 3.1 2016 page 33" href="http://viewer.zmags.com/publication/054e0926?page=33"> fell within the pre-specified equivalence mar</a> <a title="EMJ Rheumatology 3.1 2016 page 34" href="http://viewer.zmags.com/publication/054e0926?page=34"> PHARMACOVIGILANCE As with all pharmaceuticals, r</a> <a title="EMJ Rheumatology 3.1 2016 page 35" href="http://viewer.zmags.com/publication/054e0926?page=35"> REFERENCES 1. European Medicines Agency, Committ</a> <a title="EMJ Rheumatology 3.1 2016 page 36" href="http://viewer.zmags.com/publication/054e0926?page=36"> OPTIMISING PATIENT OUTCOMES THROUGHOUT THE RHEUMA</a> <a title="EMJ Rheumatology 3.1 2016 page 37" href="http://viewer.zmags.com/publication/054e0926?page=37"> College of Rheumatology (ACR) 70% response (</a> <a title="EMJ Rheumatology 3.1 2016 page 38" href="http://viewer.zmags.com/publication/054e0926?page=38"> Figure 1 continued. *2010 ACR-EULAR classificatio</a> <a title="EMJ Rheumatology 3.1 2016 page 39" href="http://viewer.zmags.com/publication/054e0926?page=39"> Given the available evidence, it could </a> <a title="EMJ Rheumatology 3.1 2016 page 40" href="http://viewer.zmags.com/publication/054e0926?page=40"> RA patients than in normal or overweight patients</a> <a title="EMJ Rheumatology 3.1 2016 page 41" href="http://viewer.zmags.com/publication/054e0926?page=41"> 16.0% at 24 weeks (p=0.001) and 18.1% vers</a> <a title="EMJ Rheumatology 3.1 2016 page 42" href="http://viewer.zmags.com/publication/054e0926?page=42"> action do not overlap completely; some patients m</a> <a title="EMJ Rheumatology 3.1 2016 page 43" href="http://viewer.zmags.com/publication/054e0926?page=43"> There is currently no clinical evidence to suppor</a> <a title="EMJ Rheumatology 3.1 2016 page 44" href="http://viewer.zmags.com/publication/054e0926?page=44"> REFERENCES 1. Smolen JS et al. </a> <a title="EMJ Rheumatology 3.1 2016 page 45" href="http://viewer.zmags.com/publication/054e0926?page=45"> opportunities and challenges. Nat Rev Rheumatol. </a> <a title="EMJ Rheumatology 3.1 2016 page 46" href="http://viewer.zmags.com/publication/054e0926?page=46"> Extension of the previous Symposium Review: Optim</a> <a title="EMJ Rheumatology 3.1 2016 page 47" href="http://viewer.zmags.com/publication/054e0926?page=47"> burden of rheumatic disease, symptoms o</a> <a title="EMJ Rheumatology 3.1 2016 page 48" href="http://viewer.zmags.com/publication/054e0926?page=48"> UNRAVELLING THE MYSTERY BETWEEN STRUCTURE </a> <a title="EMJ Rheumatology 3.1 2016 page 49" href="http://viewer.zmags.com/publication/054e0926?page=49"> How Biologics Work: What We Know and Wha</a> <a title="EMJ Rheumatology 3.1 2016 page 50" href="http://viewer.zmags.com/publication/054e0926?page=50"> ‘biosimilar’ used by the European Medicines Agenc</a> <a title="EMJ Rheumatology 3.1 2016 page 51" href="http://viewer.zmags.com/publication/054e0926?page=51"> Post-translational modification of pro</a> <a title="EMJ Rheumatology 3.1 2016 page 52" href="http://viewer.zmags.com/publication/054e0926?page=52"> methods available to detect anti-drug antibodies,</a> <a title="EMJ Rheumatology 3.1 2016 page 53" href="http://viewer.zmags.com/publication/054e0926?page=53"> Transition study Reference drug Biosimilar Singl</a> <a title="EMJ Rheumatology 3.1 2016 page 54" href="http://viewer.zmags.com/publication/054e0926?page=54"> traceability through the pharmaceutical suppl</a> <a title="EMJ Rheumatology 3.1 2016 page 55" href="http://viewer.zmags.com/publication/054e0926?page=55"> 5. Smolen JS et al. EULAR rec</a> <a title="EMJ Rheumatology 3.1 2016 page 56" href="http://viewer.zmags.com/publication/054e0926?page=56"> org.uk/about_bsr/press_releases/bsr_ supports_the</a> <a title="EMJ Rheumatology 3.1 2016 page 57" href="http://viewer.zmags.com/publication/054e0926?page=57"> PRECISION MEDICINE: MAXIMISING TREATMENT BENEFIT</a> <a title="EMJ Rheumatology 3.1 2016 page 58" href="http://viewer.zmags.com/publication/054e0926?page=58"> Average daily dose (mg/day) No use <7.5 ≥7.5 Dea</a> <a title="EMJ Rheumatology 3.1 2016 page 59" href="http://viewer.zmags.com/publication/054e0926?page=59"> prescription for a GC at some point in th</a> <a title="EMJ Rheumatology 3.1 2016 page 60" href="http://viewer.zmags.com/publication/054e0926?page=60"> Mean change from baseline in DAS28 0.0 -0.5 -1.0</a> <a title="EMJ Rheumatology 3.1 2016 page 61" href="http://viewer.zmags.com/publication/054e0926?page=61"> effectiveness of tocilizumab monotherapy.32 CDAI </a> <a title="EMJ Rheumatology 3.1 2016 page 62" href="http://viewer.zmags.com/publication/054e0926?page=62"> before they become apparent; therefore, surrogate</a> <a title="EMJ Rheumatology 3.1 2016 page 63" href="http://viewer.zmags.com/publication/054e0926?page=63"> the reasons behind the phenomenon are complex and</a> <a title="EMJ Rheumatology 3.1 2016 page 64" href="http://viewer.zmags.com/publication/054e0926?page=64"> Canadian population. RMD Open. 2015; 1(1):e000078</a> <a title="EMJ Rheumatology 3.1 2016 page 65" href="http://viewer.zmags.com/publication/054e0926?page=65"> in Patients With RA Who Are Biologic Naïve: 6-Mon</a> <a title="EMJ Rheumatology 3.1 2016 page 66" href="http://viewer.zmags.com/publication/054e0926?page=66"> THINK RHEUMATOID ARTHRITIS: CAUSES</a> <a title="EMJ Rheumatology 3.1 2016 page 67" href="http://viewer.zmags.com/publication/054e0926?page=67"> Dendritic cell Antigen-presenting cell pre</a> <a title="EMJ Rheumatology 3.1 2016 page 68" href="http://viewer.zmags.com/publication/054e0926?page=68"> Lymphoid 40% Myeloid 40% </a> <a title="EMJ Rheumatology 3.1 2016 page 69" href="http://viewer.zmags.com/publication/054e0926?page=69"> characterisation that could identify the pathway </a> <a title="EMJ Rheumatology 3.1 2016 page 70" href="http://viewer.zmags.com/publication/054e0926?page=70"> broadening the repertoire of cells that bec</a> <a title="EMJ Rheumatology 3.1 2016 page 71" href="http://viewer.zmags.com/publication/054e0926?page=71"> inflammatory disease, and have no tenderness in th</a> <a title="EMJ Rheumatology 3.1 2016 page 72" href="http://viewer.zmags.com/publication/054e0926?page=72"> At baseline, patients had high CRP le</a> <a title="EMJ Rheumatology 3.1 2016 page 73" href="http://viewer.zmags.com/publication/054e0926?page=73"> 10. Komatsu N, Takayanagi H. Infla</a> <a title="EMJ Rheumatology 3.1 2016 page 74" href="http://viewer.zmags.com/publication/054e0926?page=74"> Abstract Reviews NATURALLY OCCURRING LUBRICANTS</a> <a title="EMJ Rheumatology 3.1 2016 page 75" href="http://viewer.zmags.com/publication/054e0926?page=75"> EULAR 2016 DNA METHYLATION AND OSTEOARTHRITIS </a> <a title="EMJ Rheumatology 3.1 2016 page 76" href="http://viewer.zmags.com/publication/054e0926?page=76"> Abstract Reviews the OA hip samples formed two d</a> <a title="EMJ Rheumatology 3.1 2016 page 77" href="http://viewer.zmags.com/publication/054e0926?page=77"> EULAR 2016 A DMS location within the g</a> <a title="EMJ Rheumatology 3.1 2016 page 78" href="http://viewer.zmags.com/publication/054e0926?page=78"> Abstract Reviews 5. Reynard LN et al. CpG methyl</a> <a title="EMJ Rheumatology 3.1 2016 page 79" href="http://viewer.zmags.com/publication/054e0926?page=79"> EULAR 2016 Thus the EULAR taskforce set out</a> <a title="EMJ Rheumatology 3.1 2016 page 80" href="http://viewer.zmags.com/publication/054e0926?page=80"> Abstract Reviews complete characterisation o</a> <a title="EMJ Rheumatology 3.1 2016 page 81" href="http://viewer.zmags.com/publication/054e0926?page=81"> EULAR 2016 PERSONALISED MEDICINE The knowledge o</a> <a title="EMJ Rheumatology 3.1 2016 page 82" href="http://viewer.zmags.com/publication/054e0926?page=82"> Abstract Reviews mediated by CB , more often exp</a> <a title="EMJ Rheumatology 3.1 2016 page 83" href="http://viewer.zmags.com/publication/054e0926?page=83"> EULAR 2016 (TNF-α, BAFF), interleukins ([IL]-</a> <a title="EMJ Rheumatology 3.1 2016 page 84" href="http://viewer.zmags.com/publication/054e0926?page=84"> Abstract Reviews the patient/population, inter</a> <a title="EMJ Rheumatology 3.1 2016 page 85" href="http://viewer.zmags.com/publication/054e0926?page=85"> EULAR 2016 A B C D E Figure 1: Immunohistology a</a> <a title="EMJ Rheumatology 3.1 2016 page 86" href="http://viewer.zmags.com/publication/054e0926?page=86"> Abstract Reviews expression of the myofibrobla</a> <a title="EMJ Rheumatology 3.1 2016 page 87" href="http://viewer.zmags.com/publication/054e0926?page=87"> EULAR 2016 modulation may represent a novel </a> <a title="EMJ Rheumatology 3.1 2016 page 88" href="http://viewer.zmags.com/publication/054e0926?page=88"> Abstract Reviews NO synthase type 1 (NOS1/nNOS) </a> <a title="EMJ Rheumatology 3.1 2016 page 89" href="http://viewer.zmags.com/publication/054e0926?page=89"> EULAR 2016 We have begun to examine whether</a> <a title="EMJ Rheumatology 3.1 2016 page 90" href="http://viewer.zmags.com/publication/054e0926?page=90"> Abstract Reviews variable results. The use o</a> <a title="EMJ Rheumatology 3.1 2016 page 91" href="http://viewer.zmags.com/publication/054e0926?page=91"> Exclusive Interviews from the American Coll</a> <a title="EMJ Rheumatology 3.1 2016 page 92" href="http://viewer.zmags.com/publication/054e0926?page=92"> EDITOR’S PICK Diag</a> <a title="EMJ Rheumatology 3.1 2016 page 93" href="http://viewer.zmags.com/publication/054e0926?page=93"> INTRODUCTION Sjögren’s syndrome (SjS) is a chron</a> <a title="EMJ Rheumatology 3.1 2016 page 94" href="http://viewer.zmags.com/publication/054e0926?page=94"> disease progression can be arrested at vari</a> <a title="EMJ Rheumatology 3.1 2016 page 95" href="http://viewer.zmags.com/publication/054e0926?page=95"> indicated that the Fas antigen is expressed</a> <a title="EMJ Rheumatology 3.1 2016 page 96" href="http://viewer.zmags.com/publication/054e0926?page=96"> Type 1 diabetes. The significance of these studies</a> <a title="EMJ Rheumatology 3.1 2016 page 97" href="http://viewer.zmags.com/publication/054e0926?page=97"> 6 Relative gene expression (8 weeks of age) 5 </a> <a title="EMJ Rheumatology 3.1 2016 page 98" href="http://viewer.zmags.com/publication/054e0926?page=98"> transcriptome database from B6.NOD-Aec1Aec2 mi</a> <a title="EMJ Rheumatology 3.1 2016 page 99" href="http://viewer.zmags.com/publication/054e0926?page=99"> and the Mer receptor tyrosine kinase: a mechanis</a> <a title="EMJ Rheumatology 3.1 2016 page 100" href="http://viewer.zmags.com/publication/054e0926?page=100"> THE RELEVANCE OF HYPERURICAEMIA *Jan </a> <a title="EMJ Rheumatology 3.1 2016 page 101" href="http://viewer.zmags.com/publication/054e0926?page=101"> in women than men. This study also found </a> <a title="EMJ Rheumatology 3.1 2016 page 102" href="http://viewer.zmags.com/publication/054e0926?page=102"> Table 1: Change in estimated glomerular filtration</a> <a title="EMJ Rheumatology 3.1 2016 page 103" href="http://viewer.zmags.com/publication/054e0926?page=103"> improvement in eGFR of 1 mL/min from the u</a> <a title="EMJ Rheumatology 3.1 2016 page 104" href="http://viewer.zmags.com/publication/054e0926?page=104"> associated with microalbuminuria in prehype</a> <a title="EMJ Rheumatology 3.1 2016 page 105" href="http://viewer.zmags.com/publication/054e0926?page=105"> Would you like to write for the EMJ blog? Interac</a> <a title="EMJ Rheumatology 3.1 2016 page 106" href="http://viewer.zmags.com/publication/054e0926?page=106"> NON-INVASIVE CARDIOVASCULAR IMAGING FOR C</a> <a title="EMJ Rheumatology 3.1 2016 page 107" href="http://viewer.zmags.com/publication/054e0926?page=107"> CV risk was 2-fold higher in female RA patients t</a> <a title="EMJ Rheumatology 3.1 2016 page 108" href="http://viewer.zmags.com/publication/054e0926?page=108"> Table 1: Comparison of traditional and modified ca</a> <a title="EMJ Rheumatology 3.1 2016 page 109" href="http://viewer.zmags.com/publication/054e0926?page=109"> Table 2: Comparison of non-invasive cardiovascula</a> <a title="EMJ Rheumatology 3.1 2016 page 110" href="http://viewer.zmags.com/publication/054e0926?page=110"> ATHEROSCLEROSIS AND ITS SURROGATE MARKERS FOR CAR</a> <a title="EMJ Rheumatology 3.1 2016 page 111" href="http://viewer.zmags.com/publication/054e0926?page=111"> (maximum diameter-baseline diameter)/baseline d</a> <a title="EMJ Rheumatology 3.1 2016 page 112" href="http://viewer.zmags.com/publication/054e0926?page=112"> at which aortic pressure waves travel, is </a> <a title="EMJ Rheumatology 3.1 2016 page 113" href="http://viewer.zmags.com/publication/054e0926?page=113"> 17. Hansel S et al. Endothelial dysfunction in </a> <a title="EMJ Rheumatology 3.1 2016 page 114" href="http://viewer.zmags.com/publication/054e0926?page=114"> PSORIATIC ARTHRITIS: A REVIEW *Farrouq Ma</a> <a title="EMJ Rheumatology 3.1 2016 page 115" href="http://viewer.zmags.com/publication/054e0926?page=115"> resulting in signs such as scaly skin plaques and</a> <a title="EMJ Rheumatology 3.1 2016 page 116" href="http://viewer.zmags.com/publication/054e0926?page=116"> disease from the other SPAs and inflammatory</a> <a title="EMJ Rheumatology 3.1 2016 page 117" href="http://viewer.zmags.com/publication/054e0926?page=117"> and steroids which treat the inflammation but not </a> <a title="EMJ Rheumatology 3.1 2016 page 118" href="http://viewer.zmags.com/publication/054e0926?page=118"> THERAPIES IN THE PIPELINE FOR </a> <a title="EMJ Rheumatology 3.1 2016 page 119" href="http://viewer.zmags.com/publication/054e0926?page=119"> used ‘off-label’, especially in refractory c</a> <a title="EMJ Rheumatology 3.1 2016 page 120" href="http://viewer.zmags.com/publication/054e0926?page=120"> Table 1 continued. Therapy Target Clinica</a> <a title="EMJ Rheumatology 3.1 2016 page 121" href="http://viewer.zmags.com/publication/054e0926?page=121"> a placebo arm. Although after 12 weeks of </a> <a title="EMJ Rheumatology 3.1 2016 page 122" href="http://viewer.zmags.com/publication/054e0926?page=122"> AGS 009) or its receptor (anifrolumab [ANIFR]), a</a> <a title="EMJ Rheumatology 3.1 2016 page 123" href="http://viewer.zmags.com/publication/054e0926?page=123"> The lack of dose response was likely due to the f</a> <a title="EMJ Rheumatology 3.1 2016 page 124" href="http://viewer.zmags.com/publication/054e0926?page=124"> arm; the response rates were 39.8% and 36.8% in t</a> <a title="EMJ Rheumatology 3.1 2016 page 125" href="http://viewer.zmags.com/publication/054e0926?page=125"> BAFF antagonists may be used in the treatment of </a> <a title="EMJ Rheumatology 3.1 2016 page 126" href="http://viewer.zmags.com/publication/054e0926?page=126"> this can be accomplished by several regimen</a> <a title="EMJ Rheumatology 3.1 2016 page 127" href="http://viewer.zmags.com/publication/054e0926?page=127"> 29. Mariette X, Gottenberg J-E. Patho</a> <a title="EMJ Rheumatology 3.1 2016 page 128" href="http://viewer.zmags.com/publication/054e0926?page=128"> IDIOPATHIC INFLAMMATORY MYOPATHIES: ASSOCIATION</a> <a title="EMJ Rheumatology 3.1 2016 page 129" href="http://viewer.zmags.com/publication/054e0926?page=129"> with cancer (CAM).1,2 This criteria has how</a> <a title="EMJ Rheumatology 3.1 2016 page 130" href="http://viewer.zmags.com/publication/054e0926?page=130"> more clearly define OM as a stand-alone entity. In</a> <a title="EMJ Rheumatology 3.1 2016 page 131" href="http://viewer.zmags.com/publication/054e0926?page=131"> In other studies, the definition of OS has </a> <a title="EMJ Rheumatology 3.1 2016 page 132" href="http://viewer.zmags.com/publication/054e0926?page=132"> anti-PM/Scl antibody was significantly associated </a> <a title="EMJ Rheumatology 3.1 2016 page 133" href="http://viewer.zmags.com/publication/054e0926?page=133"> Raynaud’s phenomenon, and ILD.4 However, </a> <a title="EMJ Rheumatology 3.1 2016 page 134" href="http://viewer.zmags.com/publication/054e0926?page=134"> Rigolet et al.42 studied a cohort of patients who</a> <a title="EMJ Rheumatology 3.1 2016 page 135" href="http://viewer.zmags.com/publication/054e0926?page=135"> Ann Neurol. 1984;16(2):193-208. 15. Dalakas </a> <a title="EMJ Rheumatology 3.1 2016 page 136" href="http://viewer.zmags.com/publication/054e0926?page=136"> UPCOMING EVENTS German Society for Rheumatology (</a> <a title="EMJ Rheumatology 3.1 2016 page 137" href="http://viewer.zmags.com/publication/054e0926?page=137"> RHEUMATOLOGY British Society for Rheumatology (BS</a> <a title="EMJ Rheumatology 3.1 2016 page 138" href="http://viewer.zmags.com/publication/054e0926?page=138"> EUROPEAN MEDICAL JOURNAL provides influential arti</a> <a title="EMJ Rheumatology 3.1 2016 page 139" href="http://viewer.zmags.com/publication/054e0926?page=139"> Buyer’s Guide • ABBVIE • AMGEN • ASTRAZENEC</a> <a title="EMJ Rheumatology 3.1 2016 page 140" href="http://viewer.zmags.com/publication/054e0926?page=140"> SUBSCRIBE TO RECEIVE THE LATEST PUBLICATIONS, NE</a>